Holen Sie sich die Stockscreener-App
1.245
2.89%
0.035
Vorhandelsmarkt:
1.24
-0.005
-0.40%
Schlusskurs vom Vortag:
$1.21
Offen:
$1.21
24-Stunden-Volumen:
3.08M
Relative Volume:
0.64
Marktkapitalisierung:
$388.84M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-63.08M
KGV:
-4.6111
EPS:
-0.27
Netto-Cashflow:
$-72.53M
1W Leistung:
+5.51%
1M Leistung:
-12.94%
6M Leistung:
+40.33%
1J Leistung:
+40.96%
1-Tages-Spanne:
$1.195
$1.255
1-Wochen-Bereich:
$1.14
$1.26
52-Wochen-Spanne:
$0.515
$1.90
Ocugen Inc Stock (OCGN) Company Profile
Firmenname
Ocugen Inc
Sektor
Branche
Telefon
484-328-4701
Adresse
11 GREAT VALLEY PARKWAY, MALVERN, PA
Vergleichen Sie OCGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.245 | 377.91M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-15 | Eingeleitet | Maxim Group | Buy |
| 2023-03-01 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | Eingeleitet | Mizuho | Buy |
| 2022-06-15 | Fortgesetzt | ROTH Capital | Buy |
| 2022-06-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-07-26 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-06-11 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
Alle ansehen
Ocugen Inc Aktie (OCGN) Neueste Nachrichten
Why institutional investors increase stakes in Ocugen Inc. (2H51) stockEarnings Overview Report & Daily Stock Trend Reports - Newser
How robust is Ocugen Inc. (2H51) stock financial positionPrice Action & Advanced Swing Trade Entry Plans - Newser
Is Ocugen Inc. (2H51) stock resilient in recession scenarios2025 Stock Rankings & Weekly Watchlist of Top Performers - Newser
Why Ocugen Inc. stock appeals to analystsWeekly Trade Analysis & Risk Controlled Swing Alerts - Newser
Can Ocugen Inc. (2H51) stock deliver consistent EPS growth2025 Volatility Report & Safe Capital Growth Stock Tips - Newser
How Ocugen Inc. (2H51) stock compares with tech leadersMarket Sentiment Report & Free Low Drawdown Momentum Trade Ideas - Newser
Is Ocugen Inc. (2H51) stock good for long term investingRisk Management & Free Community Consensus Stock Picks - Newser
How the Narrative Surrounding Ocugen Is Shifting After New Licensing and Analyst Developments - Yahoo Finance
Ocugen to Announce Third-Quarter 2025 Results and Business Update on November 5 - MSN
Ocugen Inc 2H51 Stock Analysis and ForecastEarnings Surprise Analysis & Low Cost Capital Trading - earlytimes.in
Ocugen CEO to Spotlight Gene Therapy Breakthroughs at High-Profile Growth Conference - MyChesCo
Ocugen, Inc.Common Stock (NQ: OCGN - Markets Financial Content
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
OCGN Stock Price and Chart — NASDAQ:OCGN - TradingView
Ocugen, Inc. (OCGN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Will Ocugen Inc. (2H51) stock outperform energy sector in 20252025 EndofYear Setup & Verified Trade Idea Suggestions - newser.com
Is Ocugen Inc. stock a defensive play in 20252025 Dividend Review & Real-Time Market Trend Scan - newser.com
Why retail investors favor Ocugen Inc. stockWeekly Trend Summary & AI Forecasted Stock Moves - newser.com
How Ocugen Inc. (2H51) stock trades after rate cuts2025 Price Action Summary & Verified Technical Signals - newser.com
Ocugen CEO to Present at NobleCon21-Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity Conference - The Manila Times
Ocugen CEO Dr. Shankar Musunuri to Present at NobleCon21 Conference on Advancements in Gene Therapies for Blindness Diseases - Quiver Quantitative
Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ Twenty-First Annual Emerging Growth ... - Herald and News
Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ - GlobeNewswire
Why Ocugen Inc. (2H51) stock could outperform next yearPortfolio Value Summary & AI Optimized Trading Strategy Guides - newser.com
Is Ocugen Inc. showing signs of accumulationSwing Trade & Weekly Top Performers Watchlists - newser.com
How Ocugen Inc. stock reacts to job market data2025 Momentum Check & Low Drawdown Trading Strategies - newser.com
Can Ocugen Inc. stock continue upward trendJuly 2025 Selloffs & Real-Time Volume Analysis - newser.com
Analyzing net buyer seller activity in Ocugen Inc.2025 Trading Recap & Real-Time Chart Pattern Alerts - newser.com
What hedge fund moves indicate for Ocugen Inc. (2H51) stockRisk Management & Consistent Profit Alerts - newser.com
How Ocugen Inc. stock performs in high volatility marketsWeekly Trend Summary & Weekly High Return Stock Opportunities - newser.com
Can Ocugen Inc. (2H51) stock attract ESG investments2025 Volatility Report & Fast Entry High Yield Tips - newser.com
Gene Therapy for Ocular Rare Disease Market to Exhibit Phenomenal Growth During the Forecast Period (2025–2034) Due to Expanding Pipeline and Clinical Trial Activities | DelveInsight - GlobeNewswire Inc.
Finanzdaten der Ocugen Inc-Aktie (OCGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):